0000000000053190

AUTHOR

Andrea Bauer

showing 11 related works from this author

Occupational UV-Exposure is a Major Risk Factor for Basal Cell Carcinoma

2017

The aim of this study was to investigate the role of occupational and nonoccupational ultraviolet (UV)-exposure concerning the development of basal cell carcinoma (BCC).We undertook a population-based multicenter case-control study. Patients with first incident BCC (n = 836) were propensity score matched by age and sex to controls without skin cancer (n = 836). Sociodemographic characteristics, clinical characteristics, and lifetime UV-exposure were assessed by trained investigators. The differential estimation of occupational and nonoccupational UV-exposure dosages was based on validated instruments and established reference values. Associations were assessed using multivariable-adjusted c…

AdultMaleOncologymedicine.medical_specialtySkin NeoplasmsUltraviolet RaysPopulationPopulation basedRadiation Dosage030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRisk FactorsOccupational ExposureInternal medicineOdds RatiomedicineCarcinomaHumansBasal cell carcinomaRisk factorPropensity Scoreskin and connective tissue diseaseseducationAgedAged 80 and overeducation.field_of_studyintegumentary systembusiness.industryfungiPublic Health Environmental and Occupational HealthCase-control studyDose-Response Relationship RadiationOdds ratioMiddle Agedmedicine.diseaseMulticenter studyCarcinoma Basal CellCase-Control Studies030220 oncology & carcinogenesisFemalebusinessJournal of Occupational & Environmental Medicine
researchProduct

S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis

2018

Basal cell carcinoma is the most common malignant tumor among fair-skinned individuals, and its incidence has been rising steadily in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 1 highlights new developments in genetics in particular as well as aspects regarding epidemiology, diagnosis, and histology.

Geneticsmedicine.medical_specialtyMolecular epidemiologybusiness.industryIncidence (epidemiology)MEDLINEDermatologyDiseasemedicine.disease3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEpidemiologymedicineCarcinomaBasal cell carcinomaProfessional associationbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceDermatologyOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAdverse effectAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.disease3. Good healthTest (assessment)Family medicineDermatitis Allergic ContactPractice Guidelines as TopicFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up

2019

Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.

medicine.medical_specialtybusiness.industryIncidence (epidemiology)MEDLINEDermatologyDiseasemedicine.disease3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineCarcinomaProfessional associationBasal cell carcinomaDisease management (health)Intensive care medicineRisk assessmentbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

2018

BACKGROUND Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice. OBJECTIVE To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 -antihistamine-refractory CSU in Germany. METHOD A World-wide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of CU in the real-world setting, supported by the manufacturer of omalizumab. Patie…

0301 basic medicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyMedizinDrug ResistanceOmalizumabOmalizumab03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineImmunology and AllergyHumansClinical significanceChronic UrticariaDisease burdenAngioedemabusiness.industryGuidelineDermatology Life Quality IndexMiddle Aged030104 developmental biology030228 respiratory systemHistamine H1 AntagonistsQuality of LifeAntihistamineFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Very late reactions in the patch test with fragrance mix I and oak moss absolute (Evernia prunastri, INCI): Data of the Information Network of Depart…

2022

medicine.medical_specialtyTime Factors610 Medicine & healthDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineActive sensitizationmedicineImmunology and AllergyHumansddc:610610 Medicine & healthFragrance mixAllergic contact dermatitisbiologybusiness.industryParmeliaceaePatch testAbsolute (perfumery)AllergensPatch Testsmedicine.diseasebiology.organism_classificationMossDermatology030228 respiratory systemOdorantsbusiness
researchProduct

Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

2020

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the ex…

medicine.medical_specialtyEdema angioneuròticUrticariamedia_common.quotation_subjectImmunologyeducationGA2LENAngioedema; Center; Excellence; Management; Urticariaurticariacentres of reference and excelenceExcellenceimmune system diseasescentermedicineImmunology and AllergyCenter (algebra and category theory)Angioneurotic edemaskin and connective tissue diseasesmedia_commonudc:616.1Angioedemabusiness.industryangioedemahumanitiesreferenčni centri odličnostiMedicine; Allergy; ImmunologyFamily medicineexcellencemedicine.symptombusinessGlobal Allergy and Asthma European NetworkUrticàriamanagement
researchProduct

Recommendations for photopatch testing by the Photopatch Test Working Group of the German Contact Dermatitis Research Group (DKG).

2018

medicine.medical_specialtybusiness.industryDermatitis PhotoallergicPhotopatch testDermatologyPatch Testsmedicine.diseaseDermatologylanguage.human_languageGerman030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGroup (periodic table)030220 oncology & carcinogenesislanguageMedicineHumansbusinessContact dermatitisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceGuidelines as TopicDermatologyPatch testingOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.diseaseTest (assessment)Family medicineDermatitis Allergic ContactFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

17. Mainzer Allergie-Workshop

2005

medicine.medical_specialtyOtorhinolaryngologybusiness.industryFamily medicinemedicineImmunology and AllergybusinessAllergo Journal
researchProduct

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

2021

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers o…

Male0301 basic medicineSTRESSExacerbationUCAREpandemijeMedizinOmalizumabOmalizumabSERUMchronic urticaria0302 clinical medicinePandemicHealth careImmunology and AllergyChronic UrticariatreatmentChronic urticaria; COVID-19; Cyclosporine; Omalizumab; Pandemic; SARS-CoV-2; Treatment; UCAREzdravljenjeASSOCIATIONMiddle AgedCOVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatmentkronična urtikarijaINFECTIONSGA(2)LENCyclosporineFemale600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drugAdultmedicine.medical_specialtyAdolescentCoronavirus disease 2019 (COVID-19)Immunology610udc:616-097pandemicsciklosporinYoung Adult03 medical and health sciencesPatient referralmedicineHumansIn patientPatient Reported Outcome MeasurescyclosporineChronic urticariaAgedInternetPandemicSARS-CoV-2business.industrypandemicCOVID-19TreatmentDEFINITIONMedicine; Allergy; ImmunologyCross-Sectional Studies030104 developmental biology030228 respiratory systemEmergency medicineomalizumabbusinessAllergy: European Journal of Allergy and Clinical Immunology
researchProduct